Amicus Therapeutics, Inc. (NASDAQ:FOLD) Upgraded by BidaskClub to “Strong-Buy”

Amicus Therapeutics, Inc. (NASDAQ:FOLD) was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Wednesday.

A number of other research firms also recently commented on FOLD. Zacks Investment Research downgraded Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 2nd. Robert W. Baird raised their price objective on Amicus Therapeutics from $12.00 to $15.00 and gave the stock an “outperform” rating in a report on Wednesday, July 12th. ValuEngine upgraded Amicus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Bank of America Corporation cut their price objective on Amicus Therapeutics from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Thursday, May 25th. Finally, Cowen and Company restated a “buy” rating and issued a $16.00 price objective (up from $10.00) on shares of Amicus Therapeutics in a report on Tuesday, July 11th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Amicus Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $12.46.

Shares of Amicus Therapeutics (NASDAQ FOLD) traded down 2.42% during mid-day trading on Wednesday, reaching $13.28. 1,287,641 shares of the company traded hands. The stock’s market capitalization is $1.90 billion. Amicus Therapeutics has a 52-week low of $4.41 and a 52-week high of $14.05. The company’s 50 day moving average is $10.26 and its 200 day moving average is $7.65.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.02. The business had revenue of $4.20 million during the quarter, compared to analysts’ expectations of $4.16 million. The company’s revenue for the quarter was up 50.0% compared to the same quarter last year. On average, equities analysts forecast that Amicus Therapeutics will post ($1.44) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This article was reported by [[site]] and is the sole property of of [[site]]. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at [[permalink]].

In other Amicus Therapeutics news, insider Hung Do sold 29,914 shares of Amicus Therapeutics stock in a transaction that occurred on Friday, May 19th. The stock was sold at an average price of $8.00, for a total transaction of $239,312.00. Following the sale, the insider now directly owns 474,438 shares in the company, valued at approximately $3,795,504. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Life Sciences Maste Perceptive acquired 1,500,000 shares of the company’s stock in a transaction on Thursday, July 13th. The shares were acquired at an average price of $12.25 per share, for a total transaction of $18,375,000.00. The disclosure for this purchase can be found here. 3.40% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the company. Principal Financial Group Inc. increased its stake in Amicus Therapeutics by 1.8% in the first quarter. Principal Financial Group Inc. now owns 26,883 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 487 shares in the last quarter. KCG Holdings Inc. increased its stake in Amicus Therapeutics by 1.1% in the first quarter. KCG Holdings Inc. now owns 66,066 shares of the biopharmaceutical company’s stock valued at $471,000 after buying an additional 743 shares in the last quarter. Aperio Group LLC increased its stake in Amicus Therapeutics by 13.5% in the second quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 1,663 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its stake in Amicus Therapeutics by 5.2% in the first quarter. Metropolitan Life Insurance Co. NY now owns 102,462 shares of the biopharmaceutical company’s stock valued at $731,000 after buying an additional 5,041 shares in the last quarter. Finally, Creative Planning increased its stake in Amicus Therapeutics by 56.2% in the first quarter. Creative Planning now owns 16,400 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 5,900 shares in the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.